[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cel-Sci Corp (CVM)

Cel-Sci Corp (CVM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,041
  • Shares Outstanding, K 17,477
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,410 K
  • EBIT $ -22 M
  • EBITDA $ -18 M
  • 60-Month Beta 0.63
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-2.70
  • Growth Rate Est. (year over year) +37,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0700 +39.25%
on 07/15/26
1.7468 -14.70%
on 08/10/26
+0.2700 (+22.13%)
since 07/13/26
3-Month
0.9600 +55.21%
on 06/25/26
1.8600 -19.89%
on 05/19/26
+0.2900 (+24.17%)
since 05/13/26
52-Week
0.8900 +67.42%
on 05/12/26
13.4768 -88.94%
on 08/27/25
-6.8600 (-82.16%)
since 08/13/25

Most Recent Stories

More News
CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study

The published article identified low and zero (0%) PD-L1 expression and no lymph node involvement as biomarkers for selecting patients most likely to benefit from Multikine pre-surgery treatment ...

CVM : 1.4900 (+0.68%)
Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients

Peer-reviewed publication highlights Multikine's overall survival benefit in low PD-L1 oral cancer patients and expands scientific awareness as CEL-SCI is preparing to enroll patients in Confirmatory Registration...

CVM : 1.4900 (+0.68%)
CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer

Patient enrollment expected to commence at clinical centers in the U.S., Europe, Asia and later on in South America The 212-patient confirmatory study...

CVM : 1.4900 (+0.68%)
CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care

Ceremony highlights shared commitment to oncology innovation, healthcare advancement, and international collaboration Strategic partnership spans regulatory, marketing,...

CVM : 1.4900 (+0.68%)
CEL-SCI Announces Closing of Offering

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the closing of its best-efforts offering of 2,500,000 shares...

CVM : 1.4900 (+0.68%)
CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy

U.S. Confirmatory Registration Study expected to begin Summer 2026 Multikine achieved a 73% five-year survival rate versus 45% for standard of care alone in the target...

CVM : 1.4900 (+0.68%)
CEL-SCI Corporation Announces Pricing of Offering

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts offering of 2,500,000 shares...

CVM : 1.4900 (+0.68%)
CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi Arabia

Saudi Arabia Emerges as a Global Biotech Investment Hub Under Vision 2030 Senior Saudi Government, Investment and Healthcare Leaders to Attend the CEL-SCI / Amarox Signing...

CVM : 1.4900 (+0.68%)
CEL-SCI Reports Fiscal Second Quarter 2026 Results

On Track to Commence Pivotal Confirmatory Head and Neck Cancer Registration Study by Summer/Fall 2026 Signed Key Partnership with Amarox to Advance Multikine...

CVM : 1.4900 (+0.68%)
CEL-SCI Announces Closing of Public Offering

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the closing of its best-efforts public offering of 6,000,000...

CVM : 1.4900 (+0.68%)

Business Summary

CEL-SCI CORP. was formed to acquire and finance research and development of natural human interleukin-2 (``IL-2``) and lymphokine-related products and processes using the Co.'s proprietary cell culture technologies. The Co.'s proprietary product is sometimes referred to as MULTIKINEn, or buffy-coat interleukins,...

See More

Key Turning Points

3rd Resistance Point 1.5433
2nd Resistance Point 1.5167
1st Resistance Point 1.5033
Last Price 1.4900
1st Support Level 1.4633
2nd Support Level 1.4367
3rd Support Level 1.4233

See More

52-Week High 13.4768
Fibonacci 61.8% 8.6686
Fibonacci 50% 7.1834
Fibonacci 38.2% 5.6982
Last Price 1.4900
52-Week Low 0.8900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.